Cardiac Dimensions’ Device Reduces Heart Failure In Trial

Results of the 120-patient, sham-controlled REDUCE FMR trial showed Cardiac Dimensions Carillon device can significantly reduce mitral regurgitation and left ventricular volume in patients with symptomatic functional mitral regurgitation.

Mitral valve word cloud on grey background - Image
• Source: shutterstock.com

Results from the first sham-controlled trial of Cardiac Dimensions Inc.’s Carillon mitral contour system showed the implant can slow the progression of heart failure in patients with functional mitral regurgitation, also known as secondary mitral regurgitation.

Carillon is a right-heart transcatheter mitral valve repair device designed to treat primary functional mitral regurgitation grade 2+ or higher. It is deployed through a venous route starting in the jugular vein and it reshapes the mitral annulus so the separated mitral leaflets can close

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D